IFNG and neoplasm: In several clinical trials of head and neck cancer, combination treatment of ex vivo activated iNKT cells and α-GalCer-loaded-DCs led to increased circulating iNKT cells and IFNγ production, leading to stable disease or tumor regression in patients [17,116].